Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will host a virtual investor and analyst event on December 8, 2025 at 12:30 PM ET / 9:30 AM PT to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The presentation covers results scheduled for the 67th ASH Annual Meeting. Management and lead investigators will participate. A live webcast and replay will be available on the company website under Investors > Events and Presentations.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, KURA gained 7.55%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $74M to the company's valuation, bringing the market cap to $1.05B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves with some down (e.g., AVBP -0.69%, DAWN -0.94%, TNGX -0.76%) and others up (GERN +9.02%, SANA +1.63%), while KURA trades modestly higher, indicating stock-specific dynamics around its ASH-related communications.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | ASH combo data | Positive | -2.6% | Detailed ASH 2025 data on KOMZIFTI triplet in AML cohorts. |
| Dec 03 | Investor event notice | Positive | +7.5% | Announcement of Dec 8 virtual investor/analyst event on ASH data. |
| Dec 02 | First U.S. sale | Positive | -2.7% | First U.S. KOMZIFTI sale triggering $135M milestone payment. |
| Nov 25 | NCCN guideline add | Positive | +3.4% | KOMZIFTI added as Category 2A AML option in NCCN guidelines. |
| Nov 13 | FDA approval | Positive | +0.0% | FDA approval of KOMZIFTI for R/R NPM1-mutated AML patients. |
Recent major ziftomenib milestones have mostly seen positive or flat next-day reactions, but some commercialization and data updates drew negative moves, highlighting occasional divergence even on favorable news.
Over the last month, Kura reported several key milestones for KOMZIFTI (ziftomenib), including full FDA approval on Nov 13, subsequent inclusion in NCCN AML guidelines on Nov 25, and the first U.S. commercial sale with a $135 million milestone on Dec 2. Additional ASH 2025 triplet-combination data with venetoclax and azacitidine were highlighted on Dec 8. Today’s investor event announcement on Dec 3 fits into this cluster of regulatory, commercial, and clinical catalysts around ziftomenib.
Market Pulse Summary
The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the pattern seen when Kura highlighted its ASH-related investor event, which previously saw a 7.55% gain. However, history also showed negative moves after favorable commercialization and data updates, suggesting enthusiasm sometimes faded quickly. Investors monitoring such a surge might have weighed ongoing ziftomenib news flow, insider sell-to-cover activity, and overall biotech volatility when assessing how durable the strength could be.
Key Terms
acute myeloid leukemia medical
relapsed/refractory medical
AI-generated analysis. Not financial advice.
Event Scheduled for December 8, 2025 at 12:30 PM ET
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET / 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting.
The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
When is the Kura Oncology (KURA) virtual investor event to discuss ASH 2025 data?
What data will Kura Oncology (KURA) discuss at the December 8, 2025 webcast?
How can investors watch the Kura Oncology (KURA) ASH 2025 event webcast?
Who will present at the Kura Oncology (KURA) virtual analyst and investor event on December 8, 2025?
What topic will Kura Oncology (KURA) cover from the 67th ASH Annual Meeting on December 8, 2025?
